press release – Vet Clin Path Journal Sat, 16 Apr 2022 00:03:43 +0000 en-US hourly 1 press release – Vet Clin Path Journal 32 32 Izere prepares a solo art exhibition in the United States | The new times Tue, 15 Mar 2022 22:15:46 +0000

RWANDAN VISUAL ARTIST Antoine Izere is expected in the United States as he prepares for his first solo art exhibition scheduled for March 18 in Houston, Texas (USA).

The exhibition dubbed “STRIDE” was curated by Mitochondria Gallery, an art gallery specializing in the works of emerging and established artists from Africa and the African Diaspora, with a mission to educate and raise awareness about contemporary African art.

The exhibition presents a new corpus of works presented in the form of figurative paintings. This is the second collaboration between Izère and Mitochondria Gallery.

In this series, Izere paints visual representations of the significant advancements women have made in American society.

“For centuries, women have played a central role in ensuring the advancement and stability of our communities. Antoine captures this concept in a sequence of images that are contemporary while simultaneously being rooted in African history and culture,” reads in part a press release from Mitochondria Gallery.

“STRIDE is a creative progression for Antoine, infused with various artistic techniques that showcase his unique artistry”

According to the art gallery, this series of works mixes the genres of landscape, abstraction, figuration and portraiture.

Izere, 24, uses her signature impasto technique while simultaneously employing intricate brushwork.

The images of his art are rich and vibrate with an intensity that captivates the viewer. In this body of work, Antoine tells stories using layers of paint to create textural dimensions that convey physical and theoretical depth.

Itle Named New Washington State Vet | North West Sun, 13 Mar 2022 07:00:00 +0000

Amber Itle, a veterinarian with the Washington State Department of Agriculture since 2013, has been named the new state veterinarian. She succeeds Brian Joseph, who retired last summer.

Itle first joined the department in 2013 as a field veterinarian and was named assistant state veterinarian in 2017, according to a WSDA press release. After Joseph retired last summer, Itle was appointed as the acting state veterinarian.

During her time at the State Department, Itle responded to animal disease outbreaks, including avian influenza in 2014-2015 and rabbit hemorrhagic disease in 2019. In recent years, she has worked to increase awareness of the office of the state veterinarian, expanded the use of identification tags in the state’s livestock industry, built infrastructure to support animal disease traceability statewide, developed documentation of guidance in responding to animal welfare cases and provided subject matter expertise on animal care issues during natural disasters.

In the statement, Derek Sandison expressed confidence in Itle’s ability to lead the state veterinarian’s office and said she “is well regarded by our state’s livestock industry and cares deeply animal health and welfare”.

In his new role, Itle will manage the department’s animal health, avian health and animal disease traceability programs, which aim to protect animal health and welfare, contain and eradicate animal diseases and protect public health by limiting exposure to zoonotic diseases. She is the current president of the US Animal Health Association and the Western States Livestock Health Association. She also chairs several animal health and welfare committees with the National Assembly of State Animal Health Officials, according to the statement.

Itle grew up on her family’s fourth-generation dairy farm. She learned to do everything from milking cows and bottling milk at the processing plant, to running a milk route for door-to-door delivery service. Her father and sister are also veterinarians. She spent 10 years as a veterinarian for cattle, horses, and sales yards in the private sector before joining the Washington State Department of Agriculture.

Itle holds a Bachelor of Science degree from Pennsylvania State University, a Doctor of Veterinary Medicine degree from the University of Pennsylvania, and a Masters degree in Animal Welfare from Columbia University. British. Her hobbies include hiking, skiing and mountain biking, and she is married with three children.

She can be reached online at or by phone at (360) 902-1800.

Funds for cleaner water flow to twelve more counties Sun, 20 Feb 2022 20:23:00 +0000

KENTUCKY – More than $8 million in funding for water, sewer and other infrastructure improvements will soon be flowing to several counties in Kentucky as part of Gov. Andy Beshear’s Cleaner Water Program.

What do you want to know

  • Millions of dollars in additional funding was recently announced to improve water and sewer infrastructure in Kentucky
  • Kentucky’s water infrastructure received C grades in 2019 from the American Society of Civil Engineers
  • More than $5.6 million would target Allen, Barren, Clinton, Cumberland, Hart, Metcalfe, Monroe, Russell and Wayne counties to provide cleaner drinking water and improved sewage and wastewater systems
  • Officials estimate the cleaner water program will create more than 3,800 jobs in Kentucky

Beshear recently announced that more than $5.6 million will target Allen, Barren, Clinton, Cumberland, Hart, Metcalfe, Monroe, Russell and Wayne counties to provide cleaner drinking water and improved sewage and sanitation systems. improved wastewater. An additional $2.5 million will help Boyle, Mercer and Washington counties with their water infrastructure.

“Working together, we are building a better Kentucky with improved, resilient infrastructure that supports our residents and meets the needs of our growing economy,” Beshear said in a press release. “Every Kentuckian has the right to expect access to safe drinking water.”

The expansive funding comes from the Better Kentucky Plan’s $250 million Cleaner Water Program, which uses funds from the American Rescue Plan Act passed by Congress.

Officials estimate the cleaner water program will create more than 3,800 jobs in Kentucky.

Important improvements

More than $1.6 million will be provided to the Glasgow Water and Sewer Commission to advance a project to build a transmission line between the Barren River Lake water treatment plant and the site of a proposed water reservoir on the west side of town. State Rep. Steve Riley, who represents Barren and parts of Warren County, said the program will help his constituents live better, safer lives.

“With improvements to water systems, we are ensuring that Kentuckians have access to safe drinking water,” Riley said recently. “I am proud to support these improvements which will directly impact lives across the Commonwealth.”

In Monticello, $746,751 will fund a large project that will include a new pumping station in Powersburg. The City of Scottsville will use $679,000 to install new sewer infrastructure to service the new 100-acre Allen Springs Industrial Park.

In Boyle County, $1,103,985 was awarded to the Mercer County Sanitation District to improve protection of the health and water quality of Lake Herrington, which supplies water to four neighboring counties.

You can learn more about each cleaner water program award here.

More than $106 million has been awarded to recipients to fund projects since the call was announced on June 1, 2021. Eligible government agencies, such as city-owned water or sewer utilities, water commissions, water and sewer districts and counties, worked with their local area Development districts and regional water boards to submit projects for sanitation program funding some water.

There are 713 water and wastewater utilities in Kentucky. The state earned a C+ for its drinking water and a C- for its wastewater, according to the American Society of Civil Engineers’ 2019 Infrastructure Report Card.

New step towards universal blood type organs for transplantation Wed, 16 Feb 2022 23:21:44 +0000

A team of Canadian scientists has proven that it is possible to safely convert blood type in donor organs for transplantation. The findings are an important step toward creating universal type O organs, which would significantly improve fairness in organ allocation and reduce patient mortality on waiting lists.

The proof-of-concept study was published in Science Translational Medicine by a team of researchers from UBC, Latner Thoracic Research Laboratories and the University Health Network (UHN) in Toronto.

“With the current matching system, wait times can be significantly longer for patients who need a transplant based on their blood type,” says Dr. Marcelo Cypel, Surgical Director of UHN Ajmera Transplant Center and lead author of the study.

Dr Jayachandran Kizhakkedathu

Donor organs are currently matched to potential recipients based on blood type, among other criteria. Blood type is determined by the presence of antigens on the surface of red blood cells and blood vessels in organs – type A blood has antigen A, B has antigen B, blood AB has both antigens and O has none. If the blood type of a donor organ does not match the blood type of the recipient, this can trigger an immune response and the organ is likely to be rejected.

In 2018, UBC researchers, including Dr. Jayachandran Kizhakkedathu, a professor in the Department of Pathology and Laboratory Medicine, discovered a group of enzymes capable of removing antigens from the surface of cells.

For this new study, the enzymes were delivered to the lungs using the Ex Vivo Lung Perfusion (EVLP) circuit, successfully removing the antigens.

“Enzymes are Mother Nature’s catalysts and they perform particular reactions,” said UBC biochemist Dr. Stephen Withers. “This group of enzymes that we found in the human gut can cleave the A and B antigen sugars on red blood cells, converting them into universal type O cells.”

“In this experiment, it opened a gateway to create universal blood-type organs. This is a great partnership with UHN and I was amazed to learn more about the ex vivo infusion system and its impact on transplants. It’s exciting to see our findings translated into clinical research.

Dr. Kizhakkedathu and Dr. Withers went on to found ABOzymes Biomedicala UBC spin-off company working to commercialize enzyme technology.

“There are already upcoming perfusion technologies for the kidneys, so this technology should be transferable to the kidneys, and potentially to other organs,” says Dr. Kizhakkedathu, also a fellow at UBC’s Center for Blood Research.

Addressing wait times for organs

In 2019, 250 Canadians died while waiting for an organ transplant. Type O patients wait on average twice as long to receive a lung transplant as type A patients, says Dr. Aizhou Wang, scientific associate at Latner Thoracic Research Laboratories and first author of the study.

“That translates into mortality. Type O patients who need a lung transplant have a 20% higher risk of dying while waiting for a matching organ to become available,” says Dr. Wang.

This disparity is also present for other organs where a type O or B patient requiring a kidney transplant will be on the waiting list for an average of four to five years, compared to two to three years for types A or AB.

“If you convert all organs to universal type O, you can eliminate this barrier completely,” says Dr. Wang.

The experience

This proof-of-concept study was performed at the Latner Chest Research Laboratories. The experiment used the EVLP system developed in Toronto as a processing platform. The EVLP system pumps nourishing fluids through the organs, allowing them to be warmed to body temperature, so they can be repaired and improved prior to transplantation.

Human donor lungs not suitable for transplantation from type A donors were placed in the EVLP circuit. One lung was treated with a group of enzymes to remove antigens from the surface of the organ, while the other lung, from the same donor, remained untreated.

The team then tested each lung by adding type O blood to the circuit, which should trigger an immune response and organ rejection. While the untreated lung showed signs of rejection, the lung treated with the enzymes did not.

“Having universal organs means we could break down the blood-matching barrier and prioritize patients by medical emergency, thereby saving more lives and wasting fewer organs,” adds Dr. Cypel, who is also a professor in the Department of surgery from the University of Toronto and holder of the Canada Research Chair in Lung Transplantation.

The study was an interdisciplinary effort across multiple organizations in Canada, including UHN, University of Toronto, University of British Columbia and University of Alberta.

“By exchanging ideas across disciplines and across the country, we have become a collaborative effort to tackle an important problem in organ transplantation,” says Dr. Wang.

The team of researchers is working on a clinical trial proposal within the next 12 to 18 months.

This story is adapted from a press release about UHN website.

TTU School of Veterinary Medicine Welcomes New Professor of Immunology | KLBK | KAMC Sat, 12 Feb 2022 23:50:09 +0000

LUBBOCK, Texas (PRESS RELEASE) — Here is a press release from Texas Tech University:

Thousands of miles away in southern Brazil, Fernanda Trindade da Rosa grew up in a small, thriving farming community. Little did she know then that her education would lead to training, degrees and a career in animal health.

She quickly understood the infinite possibilities of One Health that go beyond animal health. It was then that she narrowed her focus to explore new solutions that will benefit the health of animals, humans and ecosystems.

Her journey now takes her far from home to Amarillo; a community where agriculture also thrives. After years of honing her skills and knowledge, she brings her passion to Texas Tech University School of Veterinary Medicine at Amarillo (SVM) as an Assistant Professor of Immunology. She took office on January 3.

“’A goal without priority is impotent.’ This quote has been part of my life and I felt this energy during my first visit to TTU SVM,” said Fernanda Rosa. “I am delighted to be part of such a team where everyone’s priority is to have a positive impact on the student’s career path from day one. I am excited to see the outstanding future professionals who will graduate from this school in a few years, and I am grateful to be part of their journey.

Fernanda Rosa has an integrative background where she particularly enjoys researching nutrition, inflammation and molecular techniques, and has worked with many different species. His distinctive skill set is so applicable to the practice of One Health.

For Fernanda Rosa, Amarillo is the perfect place for her research because she looks forward to collaborating with other experts at Texas Tech University Health Science Center at Amarillo (TTUHSC). There are also plenty of livestock operations in the area that will allow him to really get started on discovering One Health solutions.

In addition to being an exceptional researcher, she has a burning desire to mentor students and pass on the knowledge she has acquired over the years. She brings the same level of energy to Texas Tech for teaching and training those with a passion for research and discovery.

“We’ve all heard so much about the importance of immunity over the past 2 years,” said Guy Loneragan, Dean of the School of Veterinary Medicine. “Dr. Rosa’s expertise in immunity and nutrition will pay off as she discovers ways to understand and improve ways to promote health and productivity, and fight disease. We We are thrilled that she has joined our school and our community here in Amarillo.

Fernanda Rosa began her career as an intern at the Mammalian NutriPhysioGenomics Laboratory at the University of Illinois. She was intrigued by how certain nutrients can play an important role in systemic infection, and that’s when she became fascinated with nutritional immunology.

However, it wasn’t until she earned her master’s and doctoral degrees that she began to interweave her training as an animal scientist with human health. This was the defining moment for her to start focusing her research on One Health.

Fernanda Rosa joins SVM after completing her postdoctoral fellowship at the University of Arkansas Nutritional Immunology Laboratory for Medical Sciences. There, she acquired a high quality training in One Health.

“Dr. Rosa’s work on gut microbial composition and immune response in infancy is critical in addressing the importance of nutrition and metabolism in infant development,” said Thu “Annelise” Nguyen, Dean research associate and professor of toxicology “She will develop a research program that will use animal models and in vitro experiments to study the biological mechanism involved in the diet-related effect on the immune system. We are delighted that she is developing this research program here at SVM.

She received her bachelor’s degree in animal science from the Federal University of Pelotas, Brazil, in 2014, and her master’s degree in animal science from Oregon State University in 2016. Three years later, she graduated from South Dakota State University with his doctorate in biological sciences. .

She is a member of the Society for Experimental Biology and Medicine, American Society for Nutrition, Honor Society of Agriculture Gamma Sigma Delta, American Dairy Science Association, and American Society of Animal Science.

Fernanda Rosa joins a growing and dynamic team of faculty and staff at SVM. The school welcomed its first class in August 2021, and it is excited to begin working with faculty and students to help them make new research discoveries that will benefit Texas, the nation, and the world.

About the School of Veterinary Medicine
Through the generosity of Amarillo and Texas communities and the commitment of legislators across the state, Texas Tech University School of Veterinary Medicine at Amarillo was established in 2018. In March 2021, the school was awarded the very important status of provisional. American Veterinary Medical Association (AVMA) Council on Education (COE) accreditation and welcomed its first cohort of students in August 2021.

The School of Veterinary Medicine recruits and selects students who are passionate about serving rural and regional communities. Its curriculum focuses on the skills and abilities needed to succeed in the types of practice that support these communities. Texas Tech University’s innovative and cost-effective model partners with the broader veterinary practice community across the state to provide clinical and real-world experiential learning.

(Texas Tech University press release)

Animal Health Market Size to Reach USD 79.29 Billion in 2028 | Rising adoption of pets across the globe and growing number of online retail stores offering pet health products are key factors fueling the growth of the global market Tue, 25 Jan 2022 15:15:00 +0000

NEW YORK, January 25, 2022 /PRNewswire/ — The global animal health market is expected to reach $79.29 billion in 2028 and record a stable revenue CAGR of 5.9% over the forecast period, according to the latest report published by Reports and Data. The key factors driving the revenue growth of the global market are high prevalence of various zoonotic and foodborne diseases and infections, increasing research and development activities in veterinary medicine, and supportive government initiatives.

Reports and data logo

Animal health involves caring for animals with timely vaccinations, routine health checkups, and veterinary care visits. Animals have been widely used for agricultural processes, animal husbandry and as pets across the world for many centuries. However, these animals are prone to various diseases and infections. Pet owners have become aware of the importance of maintaining animal health by performing routine testing for early disease detection and treatment. At the same time, many public and private bodies have focused on providing better treatment facilities and funding research laboratories working on animal diseases and zoonotic diseases. Various market players are focusing on the development of cost-effective animal health products. The revenue growth of the global market is attributed to factors such as growing internet and e-commerce penetration, growing number of veterinary clinics and hospitals across the globe, and increasing investment in research activities and development.

However, the strict government standards regarding the approval of animal drugs and the lack of animal health awareness, as well as the inappropriate dosage of antibiotics and parasiticides in many underdeveloped countries are key factors that are expected to hamper the global market revenue growth over the forecast period.

Request a sample report –

Some highlights of the report:

  • Among the product types, the diagnostics segment is expected to register the fastest revenue CAGR during the forecast period due to rising prevalence of various animal diseases, rising animal health expenditures, growing number of veterinary clinics and hospitals equipped with the latest diagnostic equipment and procedures.

  • On the basis of animal type, the companion animal segment is expected to register a rapid CAGR in revenue between 2021 and 2028 due to factors such as increasing adoption of pets for companionship across the world, l improved veterinary services and increased awareness of companion animal health and routine health checkups. Additionally, public and private funding of veterinary research and government initiatives to support companion animal care globally are driving the segment’s revenue growth.

  • On the basis of end-use, veterinary hospitals and clinics segment is expected to account for the largest share of revenue during the forecast period owing to improved animal health infrastructure, increased incidence of various infections and diseases in animals, the increasing number of routine tests and the availability of the latest treatment and diagnostic facilities in many veterinary clinics and hospitals.

Request a custom research report @

  • Europe is expected to record steady revenue growth over the forecast period owing to factors such as growing adoption of pets in the region, high consumption of animal products, increasing prevalence of animal diseases, the availability of advanced diagnostic and treatment services.

  • Asia Pacific market revenue is expected to rise at a rapid CAGR of 10% during the forecast period due to high prevalence of various zoonotic diseases, growing adoption of companion animals such as dogs and cats among the elderly population and children, rapid urbanization and rising disposable income. In addition, growing pet and animal health awareness, routine checkups and testing, and the availability of the latest animal health products and diagnostic equipment are fueling Asia Pacific market growth.

  • Zoetis Inc., Ceva Santé Animale, Merck Animal Health, Vetoquinol SA, Boehringer Ingelheim International GmbH, Bayer AG, Virbac, Heska, Nutreco NV, Novartis International AG, Elanco Animal Health Inc., Biogenesis Bago SA, Thermo Fisher Scientific, Dechra Pharmaceuticals Plc. and Tianjin Ringpu Biotechnology Co Ltd. are key companies operating in the global animal health market.

To identify key industry trends, a research study at

For the purposes of this study, Reports and Data has segmented the global animal health market on the basis of animal type, product outlook, dosage, distribution channel, end-use, and region:

Animal Type Outlook (Revenue, billion USD, 2018-2028)

  • Production animals

  • Pets

Product outlook (Revenue, billion USD, 2018-2028)

  • Vaccines

  • Medications

  • Food additives

  • Diagnostic

Dosing outlook (Revenue, billion USD, 2018-2028)

  • Oral

  • Parenteral

  • Topical

  • Transdermal

Distribution Channel Insights (Revenue, billion USD, 2018-2028)

End-use prospects (Revenue, billion USD, 2018-2028)

Buy Premium Research Report @

Regional Outlook (Revenue, USD Billion, 2018-2028)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Explore trending research reports by reports and data:

The size of the vaccine market was $42 billion in 2020 and is expected to record a steady revenue CAGR of 7.3% over the forecast period. The key factors driving the global market revenue growth are increasing prevalence of various diseases, government efforts to increase vaccination campaigns across the globe, and rapid advancements in vaccine technologies.

The in-vivo toxicology market size was $5.0 billion in 2020 and is expected to register a CAGR of 5.4% over the forecast period. Growing research and development activities in the pharmaceutical industry and increasing demand for personalized drugs are the major factors propelling the revenue growth of the global in vivo toxicology market.

Full Metabolic Panel (CMP) Testing market size was $12.59 billion in 2020 and is expected to register a CAGR of 7.8% over the forecast period. Key factors, such as increasing prevalence of chronic disorders and increased disease awareness, early diagnosis and treatment of diseases, are expected to drive the revenue growth of the global market.

Mammography equipment market size was $2.5 billion in 2020 and is expected to register a CAGR of 10.7% over the forecast period. Major factors driving the market revenue growth, increasing prevalence of breast cancer, radiation exposure and excessive alcohol consumption.

The clinical laboratory test market size was $189.8 billion in 2020 and is expected to register a CAGR of 7.3% over the forecast period. The steady growth of the global market is attributed to the expanding geriatric population, rising health awareness among people, and increasing need for early and accurate diagnosis of diseases.

About reports and data

Reports and Data is a market research and consulting firm that provides syndicated research reports, custom research reports and consulting services. Our solutions are uniquely focused on your goal of locating, targeting and analyzing changes in consumer behavior across demographics, across industries, and helping customers make smarter business decisions. We offer market intelligence research ensuring relevant, fact-based research across multiple sectors including healthcare, touchpoints, chemicals, commodities and energy. We are constantly updating our search offerings to ensure that our clients are aware of the latest trends existing in the market. Reports and Data has a strong base of experienced analysts from a variety of areas of expertise. Our industry experience and ability to develop a workable solution to any research problem gives our clients the ability to secure an edge over their respective competitors.


Jean W
Business Development Manager
Reports and data | Web:
Direct line: +1-212-710-1370
LinkedIn | Twitter | Blogs

Read the latest press release @



View original content:–increasing-adoption-of- companion -the-animals-in-the-world-and-the-growing-number-of-online-retail-stores-offering-pet-health-products-are- key-factors-powering-gl-301467605.html

SOURCE reports and data

American Cancer Society calls on lawmakers to tax cigarettes and focus on public health | Politics Fri, 14 Jan 2022 22:16:00 +0000

INDIANAPOLIS—Indiana currently ranks sixth in the nation for adult smokers, according to the CDC.

Today, organizations like the American Cancer Society Cancer Action Network (ACS CAN) are sharing their concerns about tobacco use in Indiana. ACS CAN’s Raise It For Health campaign is pushing Indiana state legislators to raise the tobacco tax by $2, from the current rate of $0.995 for a 20-cigarette pack.

Bryan Hannon, ACS regional government relations director and member of the Raise It For Health coalition, said public health has not been treated as an important issue by lawmakers.

“I wish they would do something positive for public health,” Hannon said. “Public health has been ignored for too long in Indiana – bigger than COVID-19, bigger than vaccinations.”

Hannon also said that with lawmakers ignoring public health, more problems are created downstream, and if tobacco taxes were increased, the money could be better spent elsewhere.

“It would increase revenue for public health programs,” he said.

ACS CAN’s other concern for lawmakers is to improve access to colorectal screenings.

“We know colorectal cancer is one of the most preventable forms of cancer if Hoosiers have access to screenings,” Hannon said in a press release. “ACS CAN is asking lawmakers to prioritize the elimination of cost sharing for all preventative colorectal cancer screenings, including follow-up colonoscopies after an abnormal stool-based test.

“Several other states have already passed this type of legislation, and it’s time for Indiana to do the same.”

Illinois is 21st on the CDC’s adult smokers list, which may be because the state has a much higher tobacco tax at $2.98 per pack. In the city of Chicago, smokers must pay $8.17 in taxes to buy a 20-pack, with city, state, and federal taxes combined.

Hannon praised Rep. Ann Vermilion, R-Marion, and Rep. Brad Barrett, R-Richmond, for co-authoring 2021 HB 1007, which highlighted Hoosier’s health and safety.

Rep. Robin Shackleford, D-Indianapolis, was another co-sponsor of the bill. She said that every year Indiana gets closer to a possible tobacco tax increase, but in the past lawmakers have faced a lot of backlash from Hoosiers.

“It’s just hard to increase it once people figure out what something costs. You get a lot of pushback from the tobacco industry, from tobacco users,” Shackleford said. “So you get backlash from both sides who don’t want to see this tax increase. We tried several attempts to increase it, but at the same time, it’s just that a lot of people come out in opposition.

Shackleford said that in the future, the tobacco tax could be discussed again.

“I’m sure we’ll see him come back next year because it has to be done in a budget cycle,” Shackleford said. “I thought it was almost going to happen last year, but I think we kind of got distracted by some of the COVID-19s and worked on these funding bills. Hopefully this is something we can pass in the future.

In 2019, Raise It For Health conducted a study asking Hoosiers what they would think of a $2 tobacco tax increase. Seventy percent of voters were in favor and only 29% opposed.

Hannon said his organization understands that new public health legislation will not be enacted overnight due to the shortness of the 2022 session, but he thinks the 2023 session could focus on issues such as tobacco use and obesity, which have also been shown to increase the negative effects of COVID-19.

Ashlyn Myers is a reporter for, a news website powered by Franklin College journalism students.

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop New Patented Molecular Signatures for Biologic Therapeutic Breeding in Rheumatoid Arthritis Sun, 09 Jan 2022 17:00:00 +0000

SAN DIEGO, January 09, 2022 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University in London, today announced the signature of a research collaboration and an exclusive license agreement. The collaboration will focus on the development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize the selection of therapeutic agents for patients with rheumatoid arthritis. (PR). Both parties will contribute to the development of patent-pending tests, leading to the commercialization of new molecular tests that segment patients based on gene expression in their synovial tissue biopsies.

RA is estimated to affect approximately two million patients in the United States and is twice as common in women as in men and may be difficult to manage due to the variability in response to treatment of an patient to another. The selection of therapeutic agents for patients with RA remains a significant unmet need. Patients with RA often try several therapies empirically before finding one that decreases the activity of their disease. Placing a patient with RA on ineffective therapy risks advancing and aggravating the disease, further damaging the joints, and wasting a great deal of expense on expensive therapeutic agents. There is currently no reliable test to predict a positive patient response prior to the selection of commonly prescribed biological therapeutic agents.

Based on Professor Costantino Pitzalis and Dr Myles Lewis’s definition of molecular pathology of disease course and response to treatment, Exagen has acquired an exclusive worldwide license for a family of patent-pending tests relating to RNA expression models used in predicting patient response to prescribed csDMARDs and biologic therapies for RA. The tests use minimally invasive synovial tissue biopsies as input, which are then evaluated for RNA expression data. This data is then processed by proprietary algorithms that provide actionable information about the predicted csDMARD and the biological therapeutic response for patients with RA based on the RNA expression patterns of an individual patient.

Professor Pitzalis, Professor of Rheumatology in Arthritis and Deputy Director of the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry at Queen Mary University in London, said: “I am delighted to be a part of this research collaboration with Exagen and I look forward to contributing to the development of diagnostics aimed at integrating molecular pathology into clinical algorithms to better define specific pathways leading to disease diversity in individual patients. This would better inform clinicians about patient prognosis and improve their ability to make informed decisions about prescribing drugs. Exagen’s track record in bringing diagnostics to market takes this opportunity to a whole new level, bringing the promise of precision medicine closer to clinical implementation.

Professor Pitzalis is a leading authority on rheumatoid arthritis. He leads a team of 50 clinical researchers and is the author of over 300 peer-reviewed publications in the field of inflammation, immunity and arthritis. Professor Pitzalis formulated this revolutionary approach to gene expression models with Dr Myles Lewis, head of the bioinformatics / biostatistics group at the Center for Experimental Medicine and Rheumatology. “We are delighted to be working with Professor Pitzalis and Dr Lewis of Queen Mary University in London to accelerate the development of their highly innovative RNA-based biomarker assays to better serve patients with RA. Professor Pitzalis is a well-respected thought leader in arthritis research, and Exagen looks forward to working with his group to deliver exciting and revolutionary products to improve the continuum of care for patients with the disease. rheumatoid arthritis, ”said Ron Rocca, President and CEO of Exagen Inc.“ Exagen is committed to developing and commercializing these tests to inform treatment decisions throughout the patient’s journey with RA. We intend to market the new tests under the name AVISE® RADR (Rheumatoid Arthritis Drug Response).

For more information on AVISE® RADR, please visit

About Exagen inc.

Exagen is dedicated to transforming the continuum of care for patients with debilitating and chronic autoimmune diseases by enabling rapid differential diagnosis and optimizing therapeutic intervention. Exagen has developed and markets a portfolio of innovative test products under its AVISE® brand, many of which are based on our proprietary Cell-Bound Complement Activation Products technology, or CB-CAPs. Exagen’s goal is to enable providers to improve patient care through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune diseases, including rheumatoid arthritis and lupus. For more information, please visit

About Queen Mary University of London and Queen Mary Innovation Ltd

Queen Mary University of London is a leading research intensive university with over 28,000 students representing over 160 nationalities.

A member of the prestigious Russell Group, we work in the humanities and social sciences, medicine and dentistry, as well as science and engineering, with inspiring teaching directly informed by our research.

In the most recent Research Excellence Framework, we were ranked 5th nationally for the proportion of research results that were world-class or internationally excellent. We offer more than 240 degree programs and our reputation for excellent teaching has been recognized with a silver medal in the 2017 Teaching Excellence Framework (TEF) awards.

Queen Mary Innovation Ltd (QMI) is Queen Mary’s wholly owned technology transfer company and is responsible for the commercialization and management of the University’s intellectual property and portfolio of spin-off companies. QMI protects and exploits the intellectual property derived from Queen Mary’s research and helps to maximize the economic and societal impact of this research. QMI Biopharma’s Associate Director of Marketing, Dr. Michele Hill-Perkins, led the negotiation and licensing transaction for QMUL.

For more information on QMI, please visit

Forward-looking statements

Exagen cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of collaboration with Queen Mary University, London and any potential development and commercialization of new patented molecular signatures for the diagnosis, prognosis and surveillance of diseases. autoimmune. The inclusion of forward-looking statements should not be taken as a representation by Exagen that any of its plans will be realized. Actual results may differ from those presented in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the development of new molecular signatures involves a long and complex process, and the collaboration may not lead to new patented molecular signatures or generate significant commercial test products in a timely manner, or not at all; the COVID-19 pandemic may continue to negatively affect our business, financial condition and results of operations, including our collaboration and development activities; risks associated with maintaining the collaboration and license agreement; and other risks described in previous Company press releases and documents filed by Exagen with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s annual report on Form 10-K and any subsequent filing with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen makes no commitment to update such statements to reflect events that occur or circumstances that occur. exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations
Exagen inc.
Ryan douglas

Exagen inc.
Kamal Adawi, Chief Financial Officer

Mustang Bio announces targeted CAR T data for the MB-106 CD20 Fri, 07 Jan 2022 19:05:00 +0000

WORCESTER, Mass., Jan. 7, 2022 (GLOBE NEWSWIRE) – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs into therapies cells and genes in potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim phase 1/2 data on MB-106, an autologous CAR T cell therapy targeted against CD20 for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma (“NHL”) and chronic lymphocytic leukemia (“CLL”), were selected for poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings ‘American Society of Transplantation and Cellular Therapy (“ASTCT”) and the Center for International Blood & Marrow Transplant Research (“CIBMTR”), which will take place February 2-6, 2022 in Salt Lake City, Uta h (“2022 Tandem Meetings”). MB-106 is being developed as part of a collaboration between Mustang and the Fred Hutchinson Cancer Research Center (“Fred Hutch”).

Manuel Litchman, MD, President and CEO of Mustang, said, “The compelling clinical activity and favorable safety profile that MB-106 continues to demonstrate in the ongoing Phase 1/2 trial in Fred Hutch demonstrate its potential as an outpatient treatment for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma and chronic lymphocytic leukemia. We look forward to the updated data that will be presented by Fred Hutch at the 2022 Tandem Meetings, particularly for patients with diffuse large B-cell lymphoma and Waldenstrom’s macroglobulinemia. We also look forward to advancing our targeted CAR T cell therapy program MB-106 CD20 to a multi-center trial as part of the IND of Mustang during the current quarter.

The details of the presentation are as follows:

Title: High efficacy and low toxicity of MB-106, a third generation CD20 targeted CAR-T for the treatment of B-NHL and relapsed / refractory CLL
Poster Number: 225
Dates and times: Thursday February 3 from 6:45 p.m. to 8:15 p.m. and Saturday February 5 from 6:15 to 7:45 p.m.
Presenter: Mazyar Shadman, MD, MPH, associate professor, clinical research division, Fred Hutch, Seattle, WA; Physician at Seattle Cancer Care Alliance; Associate Professor, Division of Medical Oncology, University of Washington School of Medicine

For more information, please visit the Tandem Meetings 2022 website at

Note: Fred Hutch scientists played a role in the development of these discoveries, and Fred Hutch and some of his scientists may benefit financially from this work in the future.

About MB-106 (CD20 Targeted CAR T Cell Therapy)
CD20 is a membrane-integrated surface molecule that plays a role in the differentiation of B cells into plasma cells. The CAR T was developed by Mustang research collaborator Fred Hutch in the labs of the late Oliver Press, MD, Ph.D., and Brian Till, MD, associate professor in the clinical research division of Fred Hutch, and licensed exclusively from Mustang in 2017. The lentiviral vector drug substance used to transduce patient cells to create the MB-106 drug product produced at Fred Hutch has been optimized as a third generation CAR derived from fully antibody. human, and MB-106 is currently in a phase 1/2 open-label dose escalation trial in Fred Hutch in patients with B-NHL and CLL. The same lentiviral vector drug produced at Fred Hutch will be used to transduce patient cells to create the MB-106 drug product produced at Mustang Bio’s cell processing facility in Worcester, MA, for administration as part of the multicenter phase 1/2 clinical trial slated to be launched shortly as part of Mustang Bio’s IND. It should be noted that Mustang Bio made minor improvements to its cell treatment to facilitate a possible commercial launch of the product. In addition, prior to commercial launch, Mustang Bio will replace the lentiviral carrier drug substance Fred Hutch with a carrier produced by a commercial manufacturer. Additional information about the trial is available at using the identifier NCT03277729.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or acquiring an interest, to fund research and development, and to license or bring the technologies to market. Mustang has partnered with leading medical institutions to advance the development of CAR-T therapies for multiple cancers, as well as lentiviral gene therapies for severe combined immune deficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit

Forward-looking statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, without limitation, any statement relating to our growth strategy and product development programs and any other statements which are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks linked to the results of research and development activities; risks associated with the timing of the start and end of clinical trials; uncertainties related to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our filings with the SEC. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, except as required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company details :
Jaclyn Jaffe and Bill Begien
Mustang Bio, Inc.
(781) 652-4500

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576

Media Relations Contact Person:
Tony plohoros
6 degrees
(908) 591-2839

Scientists find traditional herbal medicine works against malaria Tue, 21 Dec 2021 18:43:22 +0000

Pharmacists from Ethiopia and Germany have studied Ranunculus multifidus, a yellow-flowered buttercup that has been used in traditional medicine for malaria and say it shows promise, especially with the emergence of strains resistant to chloroquine.

Each year more than 400,000 people pass away malaria – a preventable and treatable disease. It is estimated that two-thirds of deaths are in children under the age of five.

WHO said that the African region “carried over 90% of the global burden of disease”.

As the death toll has declined, progress has slowed, not least due to lack of funding, with the added stress of Covid-19 to top it off. As a result, scientists are scrambling to find new ways to treat the disease.

A medicinal plant from the buttercup family has been found to relieve symptoms of malaria. In some parts of Africa, a tea made from the leaves of Ranunculus multifidus is already used to treat malaria. Scientists wanted to study the plant to see if it actually helped treat malaria.

“Until now, it was not known which ingredients the plant contains and which of them could have a healing effect,” explains Professor Kaleab Asres of the University of Addis Ababa. Asres already knew the traditional use of the plant and initiated the study.

The active plant ingredient anemonine, according to a Press release, could eventually bring “a new approach” in the treatment of malaria. Extracts from Ranunculus multifidus “Significantly reduced symptoms in infected mice”, the team from Arba Minch University (AMU), Addis Ababa University (AAU) and Martin Luther Halle-Wittenberg University (MLU) report in the journal Molécules.

Pharmacists have infected lab mice with a particular type of parasite that causes malaria in rodents, as opposed to the parasite that causes malaria in humans. Then they used plant leaf extracts and tested their effectiveness in mice.

“We infected the animals with the Plasmodium berghei parasite, which causes malaria in some rodents including mice. In humans, malaria is caused by related species of plasmodia“, explains Betelhem Sirak of Arba Minch University.

The mice were divided into several categories: one group did not receive anemonin at all, but were treated with chloroquine, “an established and effective drug to treat malaria.” Other groups received varying doses of anemonin, from the buttercup plant. The press release makes a point of noting that the experiments “were conducted in accordance with internationally recognized guidelines for the keeping and care of laboratory animals.”

The results raised hope: “Although the extracts did not work as well as chloroquine, they nevertheless had a clearly positive effect on the course of the disease. For example, the mice lost much less weight and their body temperatures were also more stable than without treatment, ”explains Professor Peter Imming from MLU.

Scientists were able to extract anemonin from Ranunculus multifidus, although the plant “doesn’t actually contain it,” says Imming. “Anemonin is formed when the plant is injured, for example when it is crushed and the inside of its cells come into contact with air,” continues Imming. They imagine that this is the reason why the extracts prepared by crushing the plant showed the most promise.

Although they don’t know it for sure, scientists believe anemonin, like chloroquine, “affects the parasite’s metabolism,” the press release notes, but “probably attacks it in a different place.” This is an important finding, because the parasites that cause malaria, plasmodia, have developed resistance to the primary drug of choice, chloroquine, in parts of East and West Africa.

“Anemonin might have the potential to bypass this resistance,” says Imming. Yet because the way it works on plasmodia is unknown at this time, more studies are needed to find out how and why it works, and to increase its effectiveness. If the studies are successful, human testing will need to be done over several years to confirm its effectiveness in patients with malaria.

It was the in vivo (tested on live animals). The researchers also made some in vitro (tested in a test tube) studies to see if anemonin from Ranunculus multifidus works against other diseases for which it is used in traditional healing practices.

They tested for anemonin on bacteria similar to tuberculosis, but the plant extract was found to be ineffective. This was not a cause for concern, however, as Imming explains that “a substance that attacks all types of cells would also attack human cells – and therefore is poison.”

The researchers also investigated whether anemonin would work against two widespread parasite species, leishmania and schistosome in one different study recently published in Molecules. They write that “the results obtained in this investigation indicate that anemonin has the potential to be used as a model for the design of new anti-leishman and anti-ischistosomics. pharmacophores. “In short, anemonin could one day be used to fight leishmania and schistosome parasitic infections too.

Source: TRT World